Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UroSens Receives Funding and Enters into Clinical Trials

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Board of directors strengthened with key appointments.

UroSens Ltd has announced that it has received £0.5M ($0.8M) investment and has entered into clinical trials to assess the accuracy of its novel UroSens Mcm5-ELISA diagnostic test for the detection of bladder cancer.

The funding has been received from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures’ Finance for Business North East Accelerator Fund, and existing investors.

In addition to the £0.5M investment, UroSens has recently been awarded a grant of £250,000 from the Technology Strategy Board.

The new funding will be used to enable UroSens to carry out a series of clinical studies, which will see the Company working with over 1,200 patients at four leading UK hospitals.

The study is expected to be completed by October 2013. UroSens has secured ethics approval to conduct similar trials for the detection of prostate cancer.

With over 40,000 new cases of prostate cancer and 11,000 of bladder cancer each year in the UK, current diagnostic tests are unreliable, resulting in many unnecessary biopsies.

For both diseases, the UroSens Mcm5-ELISA diagnostic test is expected to significantly reduce the number of patients undergoing these invasive and costly procedures because it offers significantly more accurate diagnostic results.

The new test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the technology transfer arm of Cancer Research UK.

The UroSens Mcm5-ELISA test is compatible with established assay technologies and automated platforms and has achieved CE mark as a research use only product, which will allow the product to be commercialized throughout the EU and certain wider markets.

UroSens has also announced two appointments to strengthen its board of directors. Joining the board, effective immediately, are Mr Dean Slagel of Esperante and Dr Alex Buchan of Northstar Ventures.

Dean Slagel has been appointed Non-Executive Director and brings over 20 years of life science industry operational, business development and investing experience.

Alex Buchan has been appointed Board Observer. He joined Northstar in September 2004 following a series of senior commercial roles in the biotechnology sector at companies including Cybersense, Compugen, SDI Europe, EnSys Europe and Archaeus.

Dr Ian Campbell, CEO at UroSens, said: “These are significant steps forward for our company. We are grateful to our existing shareholders, Northstar Ventures and Esperante for the investment. Alongside our successful TSB grant application, this new funding enables us to progress with clinical trials and increase the pace of our commercial development.”

Dr Alex Buchan of Northstar Ventures added: “Bladder cancer is the fifth most common cancer in the UK, with the highest recurrence rate of any malignancy. We are delighted to have invested in UroSens, with its pioneering detection tests and technology, and I look forward to working with the UroSens team.”

Dean Slagel of Esperante commented: “Esperante is delighted to have invested in UroSens, which offers a novel and potentially ground-breaking urological cancer diagnostic being developed under the leadership of an experienced and high calibre management team. We look forward to continuing to support UroSens through to commercialization.”

The Finance for Business North East Accelerator Fund is backed by the European Regional Development Fund and the European Investment Bank.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!